The Multi-Omics Analysis of Lens Zonule Relaxation in The PACG Pathogenesis
ConditionPrimary Angle-Closure Glaucoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorZhongnan Hospital
About this trial
Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and the control group, there are differentially expressed molecules in PACG patients with zonular laxity, and a potential mechanistic network can be constructed therefrom.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Clinically diagnosed with primary angle-closure glaucoma (PACG)
Aged ≥ 50 years, no gender restriction
Case Group A: Undergoing glaucoma surgery with intraoperatively confirmed significant zonular laxity
Case Group B: Undergoing glaucoma surgery with intraoperatively confirmed normal zonular morphology
Disqualifiers
Secondary glaucoma
History of previous intraocular surgery
Systemic diseases that can cause abnormal ocular zonules
Other severe ocular diseases
Trial population
PACG patients with or without zonular laxity, as well as age-related cataract patients without a history or signs of glaucoma who served as the control group.
Trial design
Design model
Case-control
Time perspective
Other
Treatments tested in this trial
No Additional Experimental Intervention
Other interventionNo Additional Experimental Intervention
Treatment groups
150 Participants
are divided into 3 treatment groupsGroup A: Case Group A1 intervention
Group B: Case Group B1 intervention
Group C: Control Group1 intervention
Trial outcomes
Primary outcomes
1
Concentration of differentially expressed molecules in PACG patients with zonular laxity
Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and healthy control subjects, differentially expressed molecules will be identified and quantified by high-throughput omics sequencing and bioinformatics analysis in PACG patients with zonular laxity, and a potential mechanistic network will be constructed based on these molecular changes.
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov